Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects

NCT00807001 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis C (HCV)

Interventions

DRUG: IDX184

Sponsor

Merck Sharp & Dohme LLC